Reversal Agents Curb DOAC-related Bleeding but Deaths Still High Reversal Agents Curb DOAC-related Bleeding but Deaths Still High

The meta-analysis of more than 4000 patients also showed thrombotic events were more frequent with andexanet than with 4PCC or idarucizumab.Medscape Medical News
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Cardiology News Source Type: news